Continuous glucose monitoring in children with type 1 diabetes: Before and after insulin pump therapy

Rubina A. Heptulla, Holley F. Allen, Todd M. Gross, Edward O. Reiter

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: The aim of continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1 diabetes mellitus (T1DM) is to mimic as closely as possible the normal physiologic pattern seen in individuals without diabetes. This study was undertaken to determine the specific areas of improved glycemic control in subjects after initiation of insulin pump therapy and times where further improvement is needed. Research design and methods: Eight patients with T1DM (age 7.5-17 yr) wore the Continuous Glucose Monitoring System (CGMS) (Medtronic MiniMed, Northridge, CA, USA) for 3 d before and 3 months after initiation of insulin pump therapy. The CGMS, which measures interstitial glucose concentrations every 5 min for a 72-h period, was used to evaluate glucose profiles. Patients entered 4-5 fingerstick blood glucose measurements daily into the sensor for calibration. Detailed logs of food intake, exercise, and hypoglycemic symptoms were also recorded. Results: Hemoglobin A1c (HbA1C) was reduced (p<0.007) following 3 months of insulin pump therapy. Post-CSII continuous glucose profiles demonstrated an overall improvement in hourly mean glucose over a 24-h period (p<0.001) as well as a reduction in the area under the curve for glucose (27±4 prepump vs. 8.6±1.4 mg/dL/d postpump, p<0.004). This improvement was a result of an attenuation of the maximal postprandial glycemic excursions. Postbreakfast 349±24 vs. 267±16 mg/dL, p<0.003; lunch 340±16 vs. 217±20 mg/dL, p<0.003. Postdinner average similarly decreased after 3 months of CSII by 22%, p<0.04. Conclusions: Pump therapy specifically improved the postprandial glucose excursions in children.

Original languageEnglish (US)
Pages (from-to)10-15
Number of pages6
JournalPediatric Diabetes
Volume5
Issue number1
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Insulin
Glucose
Subcutaneous Infusions
Therapeutics
Lunch
Hypoglycemic Agents
Calibration
Area Under Curve
Blood Glucose
Hemoglobins
Research Design
Eating
Exercise

Keywords

  • Blood glucose selfmonitoring
  • Diabetes mellitus
  • Hyperglycemia
  • Hypoglycemia
  • Infusion systems
  • Insulin
  • Insulin-dependent diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

Continuous glucose monitoring in children with type 1 diabetes : Before and after insulin pump therapy. / Heptulla, Rubina A.; Allen, Holley F.; Gross, Todd M.; Reiter, Edward O.

In: Pediatric Diabetes, Vol. 5, No. 1, 03.2004, p. 10-15.

Research output: Contribution to journalArticle

Heptulla, Rubina A. ; Allen, Holley F. ; Gross, Todd M. ; Reiter, Edward O. / Continuous glucose monitoring in children with type 1 diabetes : Before and after insulin pump therapy. In: Pediatric Diabetes. 2004 ; Vol. 5, No. 1. pp. 10-15.
@article{1079fa944aca45229be23db4c79dcf64,
title = "Continuous glucose monitoring in children with type 1 diabetes: Before and after insulin pump therapy",
abstract = "Objective: The aim of continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1 diabetes mellitus (T1DM) is to mimic as closely as possible the normal physiologic pattern seen in individuals without diabetes. This study was undertaken to determine the specific areas of improved glycemic control in subjects after initiation of insulin pump therapy and times where further improvement is needed. Research design and methods: Eight patients with T1DM (age 7.5-17 yr) wore the Continuous Glucose Monitoring System (CGMS) (Medtronic MiniMed, Northridge, CA, USA) for 3 d before and 3 months after initiation of insulin pump therapy. The CGMS, which measures interstitial glucose concentrations every 5 min for a 72-h period, was used to evaluate glucose profiles. Patients entered 4-5 fingerstick blood glucose measurements daily into the sensor for calibration. Detailed logs of food intake, exercise, and hypoglycemic symptoms were also recorded. Results: Hemoglobin A1c (HbA1C) was reduced (p<0.007) following 3 months of insulin pump therapy. Post-CSII continuous glucose profiles demonstrated an overall improvement in hourly mean glucose over a 24-h period (p<0.001) as well as a reduction in the area under the curve for glucose (27±4 prepump vs. 8.6±1.4 mg/dL/d postpump, p<0.004). This improvement was a result of an attenuation of the maximal postprandial glycemic excursions. Postbreakfast 349±24 vs. 267±16 mg/dL, p<0.003; lunch 340±16 vs. 217±20 mg/dL, p<0.003. Postdinner average similarly decreased after 3 months of CSII by 22{\%}, p<0.04. Conclusions: Pump therapy specifically improved the postprandial glucose excursions in children.",
keywords = "Blood glucose selfmonitoring, Diabetes mellitus, Hyperglycemia, Hypoglycemia, Infusion systems, Insulin, Insulin-dependent diabetes",
author = "Heptulla, {Rubina A.} and Allen, {Holley F.} and Gross, {Todd M.} and Reiter, {Edward O.}",
year = "2004",
month = "3",
doi = "10.1111/j.1399-543X.2004.00035.x",
language = "English (US)",
volume = "5",
pages = "10--15",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Blackwell Munksgaard",
number = "1",

}

TY - JOUR

T1 - Continuous glucose monitoring in children with type 1 diabetes

T2 - Before and after insulin pump therapy

AU - Heptulla, Rubina A.

AU - Allen, Holley F.

AU - Gross, Todd M.

AU - Reiter, Edward O.

PY - 2004/3

Y1 - 2004/3

N2 - Objective: The aim of continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1 diabetes mellitus (T1DM) is to mimic as closely as possible the normal physiologic pattern seen in individuals without diabetes. This study was undertaken to determine the specific areas of improved glycemic control in subjects after initiation of insulin pump therapy and times where further improvement is needed. Research design and methods: Eight patients with T1DM (age 7.5-17 yr) wore the Continuous Glucose Monitoring System (CGMS) (Medtronic MiniMed, Northridge, CA, USA) for 3 d before and 3 months after initiation of insulin pump therapy. The CGMS, which measures interstitial glucose concentrations every 5 min for a 72-h period, was used to evaluate glucose profiles. Patients entered 4-5 fingerstick blood glucose measurements daily into the sensor for calibration. Detailed logs of food intake, exercise, and hypoglycemic symptoms were also recorded. Results: Hemoglobin A1c (HbA1C) was reduced (p<0.007) following 3 months of insulin pump therapy. Post-CSII continuous glucose profiles demonstrated an overall improvement in hourly mean glucose over a 24-h period (p<0.001) as well as a reduction in the area under the curve for glucose (27±4 prepump vs. 8.6±1.4 mg/dL/d postpump, p<0.004). This improvement was a result of an attenuation of the maximal postprandial glycemic excursions. Postbreakfast 349±24 vs. 267±16 mg/dL, p<0.003; lunch 340±16 vs. 217±20 mg/dL, p<0.003. Postdinner average similarly decreased after 3 months of CSII by 22%, p<0.04. Conclusions: Pump therapy specifically improved the postprandial glucose excursions in children.

AB - Objective: The aim of continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1 diabetes mellitus (T1DM) is to mimic as closely as possible the normal physiologic pattern seen in individuals without diabetes. This study was undertaken to determine the specific areas of improved glycemic control in subjects after initiation of insulin pump therapy and times where further improvement is needed. Research design and methods: Eight patients with T1DM (age 7.5-17 yr) wore the Continuous Glucose Monitoring System (CGMS) (Medtronic MiniMed, Northridge, CA, USA) for 3 d before and 3 months after initiation of insulin pump therapy. The CGMS, which measures interstitial glucose concentrations every 5 min for a 72-h period, was used to evaluate glucose profiles. Patients entered 4-5 fingerstick blood glucose measurements daily into the sensor for calibration. Detailed logs of food intake, exercise, and hypoglycemic symptoms were also recorded. Results: Hemoglobin A1c (HbA1C) was reduced (p<0.007) following 3 months of insulin pump therapy. Post-CSII continuous glucose profiles demonstrated an overall improvement in hourly mean glucose over a 24-h period (p<0.001) as well as a reduction in the area under the curve for glucose (27±4 prepump vs. 8.6±1.4 mg/dL/d postpump, p<0.004). This improvement was a result of an attenuation of the maximal postprandial glycemic excursions. Postbreakfast 349±24 vs. 267±16 mg/dL, p<0.003; lunch 340±16 vs. 217±20 mg/dL, p<0.003. Postdinner average similarly decreased after 3 months of CSII by 22%, p<0.04. Conclusions: Pump therapy specifically improved the postprandial glucose excursions in children.

KW - Blood glucose selfmonitoring

KW - Diabetes mellitus

KW - Hyperglycemia

KW - Hypoglycemia

KW - Infusion systems

KW - Insulin

KW - Insulin-dependent diabetes

UR - http://www.scopus.com/inward/record.url?scp=1842865714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842865714&partnerID=8YFLogxK

U2 - 10.1111/j.1399-543X.2004.00035.x

DO - 10.1111/j.1399-543X.2004.00035.x

M3 - Article

C2 - 15043684

AN - SCOPUS:1842865714

VL - 5

SP - 10

EP - 15

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 1

ER -